EA199900987A1 - Терапевтическое лечение заболеваний кожи - Google Patents
Терапевтическое лечение заболеваний кожиInfo
- Publication number
- EA199900987A1 EA199900987A1 EA199900987A EA199900987A EA199900987A1 EA 199900987 A1 EA199900987 A1 EA 199900987A1 EA 199900987 A EA199900987 A EA 199900987A EA 199900987 A EA199900987 A EA 199900987A EA 199900987 A1 EA199900987 A1 EA 199900987A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- therapeutic treatment
- skin diseases
- vascular permeability
- skin
- dermatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Abstract
Предложен способ уменьшения или подавления проницаемости сосудов, особенно повышенной проницаемости сосудов, связанной с ФПС/ФРЭС, и отеков кожи, проявляющихся в буллезных пемфигоидах, полиформной эритеме, герпетиформном дерматите, контактном дерматите/замедленной аллергии, путем применения ингибитора ПКС, селективного к β-изоэнзиму, (S)-3,4-[N,N'-1,1'-((2''-этокси)-3'''(O)-4'''-(N,N-диметиламино)-бутан)-бис-(3,3'-индолил)]-1(H)-пиррол-2,5-диона или его фармацевтически приемлемых солей.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4443197P | 1997-04-30 | 1997-04-30 | |
PCT/US1998/007808 WO1998048795A1 (en) | 1997-04-30 | 1998-04-21 | Therapeutic treatment for skin disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EA199900987A1 true EA199900987A1 (ru) | 2000-08-28 |
Family
ID=21932346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199900987A EA199900987A1 (ru) | 1997-04-30 | 1998-04-21 | Терапевтическое лечение заболеваний кожи |
Country Status (16)
Country | Link |
---|---|
US (1) | US6093740A (ru) |
EP (1) | EP0903145A3 (ru) |
JP (1) | JP2002501501A (ru) |
KR (1) | KR20010020381A (ru) |
CN (1) | CN1259866A (ru) |
AU (1) | AU7131898A (ru) |
BR (1) | BR9809343A (ru) |
CA (1) | CA2289257A1 (ru) |
EA (1) | EA199900987A1 (ru) |
HU (1) | HUP0002836A2 (ru) |
ID (1) | ID23528A (ru) |
IL (1) | IL132520A0 (ru) |
NO (1) | NO995231L (ru) |
PL (1) | PL336760A1 (ru) |
TR (1) | TR199902682T2 (ru) |
WO (1) | WO1998048795A1 (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE300957T1 (de) * | 1998-12-22 | 2005-08-15 | Genentech Inc | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
CA2395136A1 (en) * | 1999-12-22 | 2001-06-28 | The Scripps Research Institute | Angiogenesis and vascular permeability modulators and inhibitors |
US8846039B2 (en) * | 2002-04-26 | 2014-09-30 | Asan Laboratories Company (Cayman), Limited | Method for ameliorating pruritus |
US8163764B2 (en) * | 2002-04-26 | 2012-04-24 | Asan Laboratories Company (Cayman) Limited | Skincare methods |
TWI324604B (en) | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
US20070032479A1 (en) * | 2003-12-03 | 2007-02-08 | Leventer Steven M | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines |
DE102004019413A1 (de) * | 2004-04-19 | 2005-11-24 | Phenos Gmbh | Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten |
US8367609B2 (en) * | 2006-01-18 | 2013-02-05 | The General Hospital Corporation | Methods of reducing skin damage and edema |
US7455447B2 (en) * | 2006-05-19 | 2008-11-25 | Mediatek Inc. | Method and apparatus for a portable device |
CN101380317B (zh) * | 2007-09-07 | 2010-12-08 | 英属开曼群岛商安盛开发药物股份有限公司 | 减缓搔痒症的药学组合物 |
ES2633343T3 (es) * | 2011-06-13 | 2017-09-20 | The Board Of Trustees Of The University Of Illionis | Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal |
WO2018118874A1 (en) * | 2016-12-19 | 2018-06-28 | Chromaderm, Inc. | Methods of treating hyperpigmentation disorders |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ227850A (en) * | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
AU687909B2 (en) * | 1993-12-07 | 1998-03-05 | Eli Lilly And Company | Protein kinase C inhibitors |
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
HUT69164A (en) * | 1993-12-07 | 1995-08-28 | Lilly Co Eli | Improved process for producing bis-indolyl-maleimide derivatives |
US5545636A (en) * | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
US5481003A (en) * | 1994-06-22 | 1996-01-02 | Eli Lilly And Company | Protein kinase C inhibitors |
US5491242A (en) * | 1994-06-22 | 1996-02-13 | Eli Lilly And Company | Protein kinase C inhibitors |
SI0776895T1 (en) * | 1995-11-20 | 1999-04-30 | Eli Lilly And Company | Protein kinase C inhibitor |
UA54427C2 (ru) * | 1996-05-01 | 2003-03-17 | Елі Ліллі Енд Компані | Способ лечения заболеваний глаз, связанных с фактором роста эндотелия сосудов |
BR9710706A (pt) * | 1996-05-01 | 1999-08-17 | Lilly Co Eli | Tratamento terap-utico para doen-as relacionadas a vegf |
-
1998
- 1998-04-09 US US09/057,541 patent/US6093740A/en not_active Expired - Fee Related
- 1998-04-21 JP JP54706598A patent/JP2002501501A/ja active Pending
- 1998-04-21 BR BR9809343-6A patent/BR9809343A/pt not_active Application Discontinuation
- 1998-04-21 KR KR1019997010003A patent/KR20010020381A/ko not_active Application Discontinuation
- 1998-04-21 PL PL98336760A patent/PL336760A1/xx unknown
- 1998-04-21 IL IL13252098A patent/IL132520A0/xx unknown
- 1998-04-21 WO PCT/US1998/007808 patent/WO1998048795A1/en not_active Application Discontinuation
- 1998-04-21 AU AU71318/98A patent/AU7131898A/en not_active Abandoned
- 1998-04-21 EA EA199900987A patent/EA199900987A1/ru unknown
- 1998-04-21 CA CA002289257A patent/CA2289257A1/en not_active Abandoned
- 1998-04-21 ID IDW991443A patent/ID23528A/id unknown
- 1998-04-21 CN CN98804676A patent/CN1259866A/zh active Pending
- 1998-04-21 HU HU0002836A patent/HUP0002836A2/hu unknown
- 1998-04-21 TR TR1999/02682T patent/TR199902682T2/xx unknown
- 1998-04-30 EP EP98303403A patent/EP0903145A3/en not_active Withdrawn
-
1999
- 1999-10-26 NO NO995231A patent/NO995231L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0903145A3 (en) | 2001-02-07 |
WO1998048795A1 (en) | 1998-11-05 |
PL336760A1 (en) | 2000-07-17 |
US6093740A (en) | 2000-07-25 |
BR9809343A (pt) | 2000-07-04 |
CA2289257A1 (en) | 1998-11-05 |
HUP0002836A2 (hu) | 2001-02-28 |
IL132520A0 (en) | 2001-03-19 |
TR199902682T2 (xx) | 2000-05-22 |
AU7131898A (en) | 1998-11-24 |
CN1259866A (zh) | 2000-07-12 |
NO995231L (no) | 1999-12-27 |
ID23528A (id) | 2000-04-27 |
NO995231D0 (no) | 1999-10-26 |
KR20010020381A (ko) | 2001-03-15 |
EP0903145A2 (en) | 1999-03-24 |
JP2002501501A (ja) | 2002-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA199900987A1 (ru) | Терапевтическое лечение заболеваний кожи | |
EA199800969A1 (ru) | Способ лечения заболеваний, связанных с фактором роста сосудистого эндотелия | |
CA2253613A1 (en) | Therapeutic treatment for vegf related occular diseases | |
WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
EA200101089A1 (ru) | Новый способ лечения | |
ES2195638T3 (es) | Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida. | |
WO2000018316A3 (en) | Sustained release, and comfortable ophthalmic composition and method for ocular therapy | |
ATE315933T1 (de) | Therapeutische behandlung von kardiovaskularen krankheiten | |
EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
EA199900245A1 (ru) | Использование ингибиторов протеинкиназы с для получения лекарственного препарата для лечения спида | |
PT829262E (pt) | Utilizacao de inibidores de pkc para o fabrico de um medicamento para o tratamento de disfuncoes sexuais. | |
EP0940141A3 (en) | Use of PKC inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection | |
EP0940143A3 (en) | Use of PKC-inhibitors for the manufacture of a medicament for the treatment of asthma | |
NO990947L (no) | Anvendelse av inhibitorer for PKC til fremstilling av et medikament for behandling av sentralnervesystemsykdommer forbundet med HIV-infeksjon | |
AU2450900A (en) | Therapeutic nucleoside compound | |
KUBO et al. | Percutaneous Penetration of β-Blocking Agent-Fatty Acid Ion | |
RU99122488A (ru) | Способ лечения рака эндометрия | |
WO2001045741A3 (en) | Methods for preparing pharmaceutical formulations | |
EA199900243A1 (ru) | Применение ингибиторов протеинкиназы с для производства лекарственного препарата для лечения инфекции, вызванной человеческим т-клеточным лимфотропным вирусом типа 1 | |
RU2000109897A (ru) | Способ лечения диабетической нефропатии | |
RU2000108989A (ru) | Способ профилактики и лечения респираторных болезней телят | |
RU98111356A (ru) | Способ лечения ожогового шока |